T-Rx: Indian pharma majors breathe easy as US spares sector from reciprocal tariffs

Large Indian drug manufacturers experienced relief as President Trump's administration decided against imposing expected reciprocal tariffs on pharmaceuticals, which could have significantly impacted their earnings. Analysts deem future tariffs unlikely due to potential drug shortages and the influence of major pharma companies investing in the US.